{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-068819","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.319537+00:00","generated_at":"2026-06-22T08:25:30.413258+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protara Q3 net loss $7.7M; cash $107.1M; TARA-002 trials progressing","bullets":["Net loss of $7.7M ($0.68/share) vs. $10.8M ($0.96) in Q3 2021; includes $1.4M stock-based compensation.","Cash and investments $107.1M as of Sep 30, 2022; expected to fund operations into 2H2024.","R&D expense $3.5M, down from $4.1M; G&A $4.5M, down from $6.7M year-over-year.","Phase 1a dose escalation of TARA-002 in NMIBC ongoing; Phase 2 in LMs expected to start in 2023 after FDA feedback.","IV Choline Chloride IFALD study ongoing; results to inform next steps."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-068819","json":"https://secwatch.observer/filing/0001213900-22-068819.json","markdown":"https://secwatch.observer/filing/0001213900-22-068819.md","text":"https://secwatch.observer/filing/0001213900-22-068819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022068819/0001213900-22-068819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022068819/ea167960-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:25:30.413258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de2748d353511e490ee9d9bf573ec2ed1fc7ec8d","claim":"Protara Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income net loss of $7.7 million, or $0.68 per share, EPS $0.68 per share.","evidence_excerpt":"Protara Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390022068819/0001213900-22-068819-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"net loss of $7.7 million, or $0.68 per share"},{"label":"EPS","value":"$0.68 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}